Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month
Eli Lilly and Company announced price reductions of 70% for its most commonly prescribed insulins and caps patient out-of-pocket costs at $35
Stay updated with breaking news from Insulin Value Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Eli Lilly and Company announced price reductions of 70% for its most commonly prescribed insulins and caps patient out-of-pocket costs at $35
Eli Lilly has announced that it is reducing the list price of its insulin by 70% and capping out-of-pocket costs at $35 a month as part of its Insulin Value Program. Effective immediately, Lilly will automatically cap out-of-pocket costs at $35 at participating retail pharmacies for people with commercial insurance using Lilly insulin. Lilly is cutting the list price of its
Plus, a concerning rise in colorectal cancer among young people, what Chicago voters signaled to the rest of the country, and more.
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced price reductions of 70% for its most commonly prescribed insulins and an expansion of its...
The price reductions for the life-saving medication come amid criticism that unaffordable insulin may constitute a human rights abuse.